• News
  • SAN DIEGO
  • BioTech

Orexigen appoints Endicott to board

Orexigen Therapeutics Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, Friday announced the appointment of David Endicott to its board of directors.

Endicott brings more than 25 years of pharmaceutical and health care experience, serving leadership roles in the United States and internationally at Allergan Inc.

He currently serves as president of Allergan Medical in Asia Pacific and Latin America. He previously served in roles as president of Allergan Medical in Europe, Middle East and Africa.

Endicott has led Allergan's U.S. Specialty Pharmaceuticals business and established Allergan's Managed Markets group, in addition to other leadership roles since joining the company in 1986.

User Response
0 UserComments

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
3.02
  0.19  
+ 6.71%
9,938,773,000
9.37
1.84

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President